[TRUMPET] NSCLC Use Case

This dataset refers to a retrospective cohort of metastatic Non-Small Cell Lung Cancer (NSCLC) patients treated with first-line immunotherapy, either as monotherapy or in combination with chemotherapy. Immune checkpoint inhibitors represent the standard of care for advanced non-oncogene addicted NSCLC. However, only a subset of patients achieves durable clinical benefit. To improve predictive accuracy beyond currently approved biomarkers such as PD-L1, this study adopts a multiparametric approach integrating clinical, biological, molecular, and radiological variables to better characterize treatment response and prognosis.

The dataset consists of 341 patients. As it is based on real-world clinical data, some variables may be incomplete or missing due to the retrospective nature of data collection and routine clinical practice.

The dataset has been used within the framework of the European Union project TRUstworthy Multi-site Privacy Enhancing Technologies (TRUMPET) to test and validate the TRUMPET platform. In particular, it served as a real-world clinical use case for evaluating privacy-preserving, multi-site data analysis workflows.